Login
$GTBP
$5.51 -$0.07 (1.25%) Close

Company Executives

Officer Age In this role Joined 2025 pay Source
Michael Breen Also a director
CEO and Director
Title from the Form 4 dated Sep 4, 2025
64 Not stated Not stated $1,727,646
Alan Urban
Chief Financial Officer & Secretary
57 Since 2024
2 years
Not stated $739,310

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
4
serving now
Independent
3 of 3
stated in the proxy; 1 not stated
Average tenure
2.5 years
from year joined
CEO also chairs the board
Yes
Michael Breen
Director Age On board Independent Committees Other public boards 2025 pay Source
Michael Breen
64 2021
5 years
Not stated None stated None stated Paid as CEO
Charles J. Casamento
81 2023
3 years
Independent
Audit Committee · Chair
Eton Pharmaceuticals, Inc., PaxMedica, Inc., First Wave Biopharma, Inc., Relmada Therapeutics, Inc. $131,880
Hilary Kramer
62 2025
1 year
Independent
Nominating and Corporate Governance Committee · Chair
None stated $75,690
David C. Mun-Gavin
79 2025
1 year
Independent
Compensation Committee · Chair
None stated $69,551

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

4 disclosed in the proxy filed Jul 2, 2026
PDPC Advisors Inc.
PDPC is considered a related party as its chief executive officer, Paul Kessler
Cash payments amounting to $100,000
2025

Advisory Agreement for advisory services with cash payments and a pre-funded warrant issued to PDPC

PDPC Advisors Inc.
PDPC is considered a related party as its chief executive officer, Paul Kessler
Cash payments amounting to $150,000
2026

First Amendment to Advisory Agreement with cash payments and a pre-funded warrant issued to PDPC

Cytovance Biologics, Inc.
Cytovance was a related party as of the year ended December 31, 2024
Research and development expenses of $743,000 and $2,335,000
2025 and 2024

Biologic development, manufacturing and testing services under Statements of Work, with research and development expenses recognized and cash payments made

Cytovance Biologics, Inc.
Cytovance was a related party as of the year ended December 31, 2024
Approximately $847,000
2025

Pre-funded warrants issued to Cytovance to settle accounts payable

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support